Cancer Market Research Reports & Industry Analysis

Cancer is a package of diseases marked by uncurbed growth and proliferation of anomalous cells. The illness is generally assumed to be the fruit of the impact of assorted outside factors and inner forces, such as tobacco smoking, radiation exposure, chemicals’ influences, infectious agents, inherited gene mutations, hormonal disorders, immune system conditions and mutations of other origins, among others.

Thus far, the Cancer Market has already seen noticeable progress in early-stage tumor detection and cure globally. The market for Cancer diagnostics is close to explosive growth, promising to reach approximately EUR 4 billion in value by end-2015. Further, technology discoveries will continue to afford many chances of demystifying the genetic components of the sickness, identifying specific tumor types, and observing biological reaction to cancer treatments. However, the bulk of presently available therapies do not fully protect against some unwelcomed side-effects.

The research reports in this Catalogue present global, regional and nation-level analyses of the Cancer Market development trends over different time spans. The research reports identify major bizopps emerging in the Cancer Market; examine versatile Cancer diagnostic test technologies along with their applications, besides looking into other Cancer Market issues. The research reports also profile the top players and would-be entrants, as well as offer test volume and sales projections.

Found 1253 publications
Cancer Immunotherapy Market & Clinical Pipeline Insight US$ 4,200.00 US$ 3,600.00

... Hard Copy License. With more than 6 million deaths worldwide in 2013, cancer has become one of the most pressing health problems faced by ... which is one of the major reasons for cancer immunotherapy not being in widespread use. “Cancer Immunotherapy Market & Clinical Pipeline Insight” Report Highlights: ...

Jul, 2014 1990 pages
Tumor Markers: Unlocking the Mistery of the Genetic Basis of Cancer - Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence US$ 24,500.00

... tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ... of over 500 companies, universities and research centers developing new tumor markers and detection technologies. Competitive Assessments Extensive strategic assessments ...

Jun, 2014 1200 pages
Cancer Diagnostics: A Market on the Verge of Explosion - Technological Breakthroughs, Emerging Tests, Market Forecasts, Competitive Intelligence US$ 24,500.00

... market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays ... identifies specific business opportunities for suppliers. Rationale The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological ...

Jun, 2014 1200 pages
PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update US$ 9,995.00

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update SUMMARY Non-Small Cell Lung ... Uptake will be driven by the drug’s promising clinical efficacy in both squamous and non-squamous patients and strong safety profile. After Iressa and Tarceva lose ...

Apr, 2014 390 pages
Cancer Anorexia Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Cancer Anorexia. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

May, 2014 79 pages
Global Orphan Cancer Drug Market & Clinical Pipeline Insight US$ 2,400.00

... promising, it is expected that over the next few years, many drugs are likely to be developed over a range of indications including the commonly ... there would be a significant improvement in the survival rates of the patients. “Global Orphan Cancer Drug Market & Clinical Pipeline Insight” Report Highlights: ...

Jun, 2014 969 pages
The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus US$ 4,995.00

... safe products to the market. Key benefits, features and insights The cancer immunotherapy market is evolving rapidly. In this report, key stakeholders from ... PD-L1 therapeutic approaches including efficacy and toxicity assessments Understand how cancer vaccines may fit into the future market Gain insight ...

Jun, 2014
Global Breast Cancer Market 2014-2018 US$ 3,000.00

... the key trends that are emerging in the market. TechNavio's report, the Global Breast Cancer Market 2014-2018, has been prepared based on an ... years. The report also includes a discussion of the key vendors operating in this market. Key Regions Americas EMEA APAC Key Vendors Astrazeneca PLC Eli Lilly ...

Jun, 2014 117 pages
Nonmelanomatous Skin Cancer - Pipeline Review, H1 2014 US$ 2,000.00

... Review, H1 2014’, provides an overview of the Nonmelanomatous Skin Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... ) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ...

Jun, 2014 45 pages
Bladder Carcinoma - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Bladder Carcinoma - Pipeline Review, H1 2014’, provides an overview of the Bladder Carcinoma’s therapeutic pipeline. This report provides ... key players involved in the therapeutics development for Bladder Carcinoma and enlists all their major and minor projects The report ...

Jun, 2014 38 pages
Cancer Cell Therapy Market & Pipeline Insight US$ 2,400.00

... to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient.The discovery ... be in a better position to develop efficient drugs and prevent the spread of cancer.“Cancer Cell Therapy Market & Pipeline Insight” Report Highlights & Findings: ...

Jun, 2014 195 pages
Cervical Cancer Drug Market & Pipeline Insight US$ 1,200.00

... are also being analyzed. A majority of these studies were previously focusing on cervical cells in women. But in recent years, the realm of research has ... lead to the growth of abnormal cells, thus controlling the incidence of cervical cancer. “Cervical Cancer Drug Market & Pipeline Insight” Report Highlights ...

Jun, 2014 165 pages
Cancer Cytokines Therapy Pipeline Analysis US$ 1,800.00

... are related to almost all the therapeutic protein drug development processes. The cytokine and growth factor related products include antibodies ... improve quality of life. “Cancer Cytokines Therapy Pipeline Analysis” Report Highlights: Cancer Cytokines Therapy Market Overview Marketed Drug Profiles & Patent ...

Jun, 2014 231 pages
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H1 2014 US$ 2,000.00

... ’, provides an overview of the Adrenocortical Carcinoma (Adrenal Cortex Cancer)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... Carcinoma (Adrenal Cortex Cancer) and enlists all their major and minor projects The report summarizes all the dormant and ...

May, 2014 60 pages
Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany US$ 3,500.00

... Early Approval in Germany Summary GBI Research, a leading business intelligence provider, has released its latest research report, “Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany”.Due to ...

Jun, 2014 112 pages
Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support Continued Dominance of HER2 Targeted Drugs US$ 3,500.00

... business intelligence provider, has released its latest research, '‘Breast Cancer Therapeutics in Major Developed Markets to 2020 - Approval of Novel Therapies to Support ... market within the eight major geographies of the US, Canada, the top five geographies in Europe (the UK, France, Germany, Spain and Italy ...

Jun, 2014 106 pages
Small Intestine Cancer Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Clinical Trials Review, H1, 2014' provides data on the Small Intestine Cancer clinical trial scenario. This report provides elemental information and data ... across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also ...

May, 2014 116 pages
Skin Cancer Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Trials Review, H1, 2014' provides data on the Skin Cancer clinical trial scenario. This report provides elemental information and data relating to the ... relevance of data for the indicated disease. Scope Data on the number of clinical trials conducted in North America, South and Central America, Europe, ...

May, 2014 214 pages
Relapsed Multiple Myeloma Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Clinical Trials Review, H1, 2014' provides data on the Relapsed Multiple Myeloma clinical trial scenario. This report provides elemental information and data ... across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and ...

May, 2014 170 pages
Relapsed Chronic Lymphocytic Leukemia (CLL) Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... elemental information and data relating to the clinical trials on Relapsed Chronic Lymphocytic Leukemia (CLL). It includes an overview of the trial numbers and their ... number of trials for the key drugs for treating Relapsed Chronic Lymphocytic Leukemia (CLL). This report is built using data and information ...

May, 2014 185 pages
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players US$ 3,500.00

... whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked ... quotes from Key Opinion Leaders (KOL) as well as doctors using Companion Diagnostic in clinical practice. Reasons to buy Gain a high level view ...

May, 2014 281 pages
Physician Views: How do oncologists value medical affairs teams – what could they be doing better? US$ 645.00

... and value of these teams. FirstWord's latest Physician Views poll seeks to gain some insight into how physicians value the role that medical affairs personnel play. Specifically we asked US and EU5-based oncologists: How important they view medical affairs teams in enabling effective communication between ...

May, 2014
Deals in Oncology Personalized Medicine Industry – Worldwide Analysis US$ 900.00

The Personalized Medicine in Oncology Deals and Alliances of 2014 report provides comprehensive understanding and unprecedented access to the partnering deals and agreements entered into by the world’s leading healthcare companies in oncology sector. All the deals have been tracked year wise. All the deals ...

May, 2014 43 pages
MediPoint: Companion Diagnostic Tests in Oncology - US Analysis and Market Forecasts US$ 4,450.00

... whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked ... , rather than the cheaper immunohistochemistry (IHC) test that typifies HER2 testing, the value of the NSCLC market is considerably higher. Scope ...

May, 2014 423 pages
MediPoint: Companion Diagnostic Tests in Oncology - South America Analysis and Market Forecasts US$ 4,450.00

... -Pacific (APAC) regions (Japan, China, and India), and identifies the unmet needs in this companion diagnostics market. This report analyses ... to pathology laboratories. GlobalData estimates the companion diagnostic test market in South America, for breast cancer companion diagnostic tests, principally HER2 ...

May, 2014 408 pages
MediPoint: Companion Diagnostic Tests in Oncology - EU Analysis and Market Forecasts US$ 4,450.00

... tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to ... have been worth $53.2m in 2012. In the major EU, uptake of the HER2 IHC test is near saturation, and most growth will come from increases ...

May, 2014 489 pages
MediPoint: Companion Diagnostic Tests in Oncology - APAC Analysis and Market Forecasts US$ 4,450.00

... tool whose use allows the safe application of a therapy. In-vitro Companion Diagnostic tests measure the expression or presence of a specific biomarker that is linked to ... (France, Germany, Italy, Spain, and UK), Brazil, and the some of the Asia-Pacific (APAC) regions (Japan, China, and India), and identifies ...

May, 2014 446 pages
Uveal Melanoma - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Uveal Melanoma - Pipeline Review, H1 2014’, provides an overview of the Uveal Melanoma’s therapeutic pipeline. This report provides ... , along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for ...

May, 2014 41 pages
Retinoblastoma - Pipeline Review, H1 2014 US$ 2,000.00

Summary Global Markets Direct’s, ‘Retinoblastoma - Pipeline Review, H1 2014’, provides an overview of the Retinoblastoma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Retinoblastoma, complete with comparative analysis at various stages, ...

May, 2014 54 pages
Germ Cell Tumors - Pipeline Review, H1 2014 US$ 2,000.00

... Review, H1 2014’, provides an overview of the Germ Cell Tumors’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... landscape of Germ Cell Tumors The report reviews key pipeline products under drug profile section which includes, product description, MoA ...

May, 2014 51 pages
Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity? US$ 645.00

... Products Regulatory Agency (MHRA) announced the soon-to-launch 'Early Access to Medicine Scheme' (EAMS), a system which has drawn comparison to the ... derived from the process. To assess the view of expanded access programmes from the position of the physician community, FirstWord is polling oncologists based ...

Apr, 2014
Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies US$ 3,500.00

Summary GBI Research, has released the pharma report -"Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses ... diagnosis. In-depth analysis of the drug combinations used in the treatment of ovarian cancer, including analyses of their safety, efficacy, and place in the ...

May, 2014 148 pages
Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide Diversified Treatment Options US$ 3,500.00

... intelligence provider, has released its latest research: "Breast Cancer Therapeutics in Asia-Pacific Markets to 2020 - Novel HER-2 Positive Therapies Provide ... heat map of product performance In-depth pipeline analysis for global pipeline in breast cancer drugs along with clinical trial failure rate analysis ...

May, 2014 103 pages
Circulating Tumor Cells and Cancer Stem Cells Technologies: Market Research Report US$ 4,950.00

This report analyzes the worldwide markets for Circulating Tumor Cells and Cancer Stem Cells Technologies in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates ...

Jan, 2014 213 pages
MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts US$ 6,495.00

MediPoint: Companion Diagnostic Tests in Oncology - Global Analysis and Market Forecasts SUMMARY A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool ... and non-small cell lung cancer. (Q).Which are the leading tests? (Q).How are the tests performed Where are companion ...

May, 2014 592 pages
Physician Views – Are oncologists ready to embrace real-world data? US$ 645.00

... they have their own particular views on how this resource can be used to improve the treatment of patients in the future? Are they aware of the challenges ... data? To further ascertain an insight into the physician perceptive towards real-world data, FirstWord polled 192 oncologists based in the US and EU5. ...

Apr, 2014
Metastatic Breast Cancer - Pipeline Review, H1 2014 US$ 2,000.00

... Review, H1 2014’, provides an overview of the Metastatic Breast Cancer’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... ) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ...

Mar, 2014 589 pages
Hairy Cell Leukemia - Pipeline Review, H1 2014 US$ 2,000.00

... Pipeline Review, H1 2014’, provides an overview of the Hairy Cell Leukemia’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for ... ) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the ...

Apr, 2014 70 pages
New Frontiers in the US Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 9,800.00

Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400. New Frontiers in the U.S. Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the U.S. cancer ...

May, 2014 620 pages
New Frontiers in the UK Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 6,700.00

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the UK Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the UK cancer ...

May, 2014 565 pages
New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 6,700.00

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the Spanish Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the Spanish ...

May, 2014 565 pages
New Frontiers in the Japanese Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 8,800.00

Complete report $8,800. DataPack (test volumes, sales forecasts, supplier shares) $5,700. New Frontiers in the Japanese Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the ...

May, 2014 590 pages
New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 6,700.00

Complete report $6,700. DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the Italian Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the Italian ...

May, 2014 570 pages
New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 6,700.00

... . DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the German Cancer Diagnostics Market: Business Challenges, Emerging Technologies, ... during the nextfive years. The report examines trends in the German cancer diagnostics markets, reviews current and emerging assays; analyzes ...

May, 2014 585 pages
New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 6,700.00

... . DataPack (test volumes, sales forecasts, supplier shares) $4,350. New Frontiers in the French Cancer Diagnostics Market: Business Challenges, Emerging Technologies, ... during the nextfive years. The report examines trends in the French cancer diagnostics markets, reviews current and emerging assays; analyzes ...

May, 2014 585 pages
Urethral Cancer Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Urethral Cancer. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies ...

Apr, 2014 110 pages
Ureter Cancer Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... and data relating to the clinical trials on Ureter Cancer. It includes an overview of the trial numbers and their recruitment status as per the ... more Obtain discontinued trial listing for trials across the globe Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Apr, 2014 89 pages
New Frontiers in the European Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape US$ 19,700.00

Complete report $19,700. DataPack (test volumes, sales forecasts, supplier shares) $12,800. New Frontiers in the European Cancer Diagnostics Market: Business Challenges, Emerging Technologies, Competitive Landscape is Venture Planning Groups new study of the major business opportunities emerging in the ...

May, 2014 820 pages
New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape US$ 34,500.00

... . DataPack (test volumes, sales forecasts, supplier shares) $21,100. New Frontiers in Cancer Diagnostics: Global Challenges, Emerging Technologies, Competitive Landscape is Venture ... specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer ...

May, 2014 1200 pages
Oral Cavity (Mouth) Cancer Global Clinical Trials Review, H1, 2014 US$ 2,500.00

... Cancer Global Clinical Trials Review, H1, 2014' provides data on the Oral Cavity (Mouth) Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Oral Cavity (Mouth) Cancer. It includes an overview of the trial numbers and their recruitment status ...

Apr, 2014 91 pages
1 2 3 4 5 >
Skip to top